We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Philips Collaborates with Janssen on Handheld Test for Neuropsychiatric Disorders

By LabMedica International staff writers
Posted on 05 Apr 2015
Print article
Royal Philips (Amsterdam, Netherlands) has entered into a multiyear development agreement with Janssen Pharmaceutica NV (Beerse, Belgium) to develop a novel point-of-care (POC) blood test to improve the care of patients with neuropsychiatric disorders.

The collaboration unites Philips’ expertise in POC diagnostics and monitoring applications for hospital and home with Janssen’s strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for development and manufacturing of the handheld test, which will be based on Philips’ “Minicare” system currently under development. Janssen will be responsible for the clinical validation studies, as well as commercialization of the final product. Minicare is part of Philips’ Handheld Diagnostics business (Eindhoven, Netherlands), which will be expanding its production capacity in light of the new partnership.

The blood test will be based on Minicare I-20 for immunoassays, which consists of a handheld analyzer, dedicated software, and a single-use, disposable cartridge containing the application-specific test. Based on Philips’ proprietary biosensor technology, Minicare I -20 is being developed to detect multiple target molecules at low concentrations within a single blood sample and to provide the results on the analyzer display within minutes.

“Our technology can play an important role in the management of chronic diseases,” said Frans van Houten, CEO, Royal Philips, “Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform.”

“Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software can be tailored to a wide range of other pharmaceuticals,” added Mr. Van Houten.

Related Links:

Royal Philips
Janssen Pharmaceutica


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.